Alors que les derniers indicateurs relatifs à la santé des femmes témoignent de l'impact considérable qu'a le Covid-19 sur la santé sexuelle et reproductive, Action…
@dm1n1str@t0r2 February 2021
Alors que les derniers indicateurs relatifs à la santé des femmes témoignent de l'impact considérable qu'a le Covid-19 sur la santé sexuelle et reproductive, Action…
@dm1n1str@t0r1 February 2021
Aligned with our first support through the open letter signed by more than 500 organisations, GHA and more than 100 civil society organisations are now…
@dm1n1str@t0r19 November 2020
If the COVID-19 pandemic could teach us just one lesson, let it be that we - the international community - must be better prepared to…
@dm1n1str@t0r24 July 2020
A response to the Innovative Medicines Initiative’s open letter 10/07/2020 On May 25th, Corporate Europe Observatory and Global Health Advocates published two investigative reports on…
@dm1n1str@t0r10 July 2020
Noting the special challenges of the COVID-19 global pandemic, GHA welcomes the “Next Generation EU” recovery package, and the revised 7 year budget proposal, which…
@dm1n1str@t0r29 June 2020
On June 4th, 2020, the UK hosted the replenishment of Gavi, the Vaccine Alliance, providing an the international community to realign with the ambitions of…
@dm1n1str@t0r5 June 2020
This article is an updated version of a case study contained in the report "More Private than Public – The ways Big Pharma dominates the Innovative Medicines…
@dm1n1str@t0r3 June 2020
For the past 15 years, industry lobby groups have controlled the use of €3.6 billion in public EU funds for health and climate research through…
@dm1n1str@t0r25 May 2020
The report "More private than public: the way Big Pharma dominates the Innovative Medicines Initiative" is part of an in-depth work dedicated to EU’s health…
@dm1n1str@t0r25 May 2020
